# Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

> **NCT00792740** · PHASE1,PHASE2 · TERMINATED · sponsor: **Italfarmaco** · enrollment: 51 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** ITF2357
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00792740
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10-22
- **Primary completion:** 2008-12
- **Final completion:** 2009-03-11
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** As no safety warnings were detected, Interim analysis from the first 40 patients recommends to stop the trial for futility
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00792740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00792740, "Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00792740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*